You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Last Updated: November 27, 2020

DrugPatentWatch Database Preview

Litigation for INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

US Court Litigation for INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Patent	Case Name	Docket	Date Filed	Date Terminated	Cause	Court	Jury Demand	Link To Docket
7,291,132	Start Trial	Start Trial	2016-12-29	2018-10-24	15:1 Antitrust Litigation	District Court, D. Massachusetts	Plaintiff	Start Trial
>Patent	>Case Name	>Docket	>Date Filed	>Date Terminated	>Cause	>Court	>Jury Demand	>Link To Docket

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.